Current Mpox Situation
As of September 2024, Mpox continues to be a concern in the U.S., although case numbers have decreased significantly from the initial outbreak in 2022-2023. While widespread outbreaks have been contained, localized clusters persist, primarily among high-risk populations,such as individuals with multiple sexual partners. Public health efforts remain focused on monitoring and containment.

Testing Demand in 2024
Although testing demand is no longer as intense as during the peak of the outbreak, it remains steady in areas with ongoing transmission. The CDC has scaled up testing capabilities to ensure rapid detection, with up to 80,000 tests available per week. Public health agencies continue to emphasize the importance of testing in high-risk populations to prevent further spread

Adding Mpox PCR Testing: Is It Feasible?
For labs already conducting PCR testing for other infectious diseases, adding Mpox PCR is a relatively easy and cost-effective option. The FDA has authorized multiple Mpox PCR tests, and integrating them into an existing PCR setup does not require significant investment. Moreover, the demand for Mpox testing may provide labs with an opportunity to serve their communities and high-risk groups

For labs without existing PCR capabilities, however, the cost of setting up PCR infrastructure can be prohibitive. The necessary investment in equipment, staff training, and regulatory compliance may not be justified, especially since Mpox outbreaks have been largely contained. Labs considering this expansion should carefully evaluate local testing demand before making a decision

Conclusion
If your lab already offers PCR testing, adding Mpox PCR testing could be a strategic move to address niche demand in your community. However, for labs without this capacity, the cost may outweigh the benefits unless there is a significant local need for Mpox testing.

P.S. If you want to add Mpox testing to your lab, contact us.